SOUTH SAN FRANCISCO, Calif. — October 30, 2025 — Leads & Copy — BridgeBio Oncology Therapeutics, Inc. (BBOT) (Nasdaq: BBOT) will present two posters featuring BBO-10203, an oral RAS:PI3Kα interaction breaker, at the San Antonio Breast Cancer Symposium (SABCS) December 9-12 in San Antonio, Texas. Abstracts are on the SABCS website.
A late-breaking pre-clinical poster details BBO-10203’s inhibition of tumor growth alone and with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia (PS2-12-06, Abstract 3568, December 10). Kerstin Sinkevicius, PhD, VP of Pharmacology at BBOT, will present.
A trials-in-progress poster highlights BREAKER-101, a phase 1a/1b study evaluating BBO-10203’s safety, tolerability, pharmacokinetics, and efficacy in patients with advanced solid tumors (PS5-07-06, Abstract 203, December 12). Andreas Varkaris, MD, PhD, of Massachusetts General Hospital, will present.
BBO-10203 (NCT06625775) is a small molecule that blocks the RAS:PI3Kα interaction, inhibiting RAS-driven PI3Kα-AKT signaling without hyperglycemia risk. It is being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer.
BBOT aims to improve outcomes for patients with cancers driven by the two most prevalent oncogenes. For more, see www.bbotx.com and follow on LinkedIn.
Investor Contact: Heather Armstrong, Head of Investor Relations, Investors@BBOTx.com
Media Contact: Jake Robison, Inizio Evoke Comms, Jake.robison@inizioevoke.com
Source: BridgeBio Oncology Therapeutics, Inc.
